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Mediastinal Incidentalomas
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Introduction: Incidental mediastinal lymphadenopathy challenges
pulmonologists to decide on eventual further diagnostic steps. The
aim of this study was to characterize unexpected mediastinal find-
ings by imaging and pathologic analysis.
Methods: Entry criterion for this prospective explorative study was
mediastinal lymphadenopathy as an incidental finding on computed
tomography (CT) scans made for indications other than the analysis
and staging of neoplasms. Lymph node dimensions were measured
on CT scan. Subsequent diagnostic investigations were positron
emission tomography, endoscopic ultrasound- or endobronchial ul-
trasound-guided punctures, and clinical follow-up.
Results: Eighty-three patients from eight hospitals met the entry
criteria. The median number of Naruke stations with enlarged nodes
was 7 (range 3–9). The median size of all nodes measured varied
between 6 and 14 mm. The median number of lymph node stations
with nodes of at least 10 mm was 3 (range 0–8). Hilar node
enlargement was detected in 77% of patients. No definitive diagno-
sis was obtained in 7 of 83 (8%) patients. Lymphocytes were found
in 55 of 83 (66%) and sarcoidosis in 18 of 83 (22%) of aspirates.
Positron emission tomography showed metabolic activity in 87% of
patients. Follow-up CT scans were available for 36 of 62 (58%)
patients without a classifying diagnosis. Two patients developed
lung cancer 2 years after initial analysis.
Conclusions: Incidental mediastinal lymph nodes on CT are charac-
terized by multiplicity, relative small sizes, and coexistence with hilar
lymphadenopathy in the majority of patients. These nodes often display
increased metabolic activity. The low predictive value for malignancy
justifies a restrictive attitude toward invasive diagnostic testing.
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(J Thorac Oncol. 2011;6: 1345–1349)
Enlarged mediastinal lymph nodes may be detected inci-dentally on computed tomography (CT) scan of the chest
and often raise the question whether further analysis is
indicated. Nowadays, CT is easily accessible and made for a
broader range of indications including pulmonary embolism
and coronary artery imaging. Thus, incidentally enlarged
mediastinal nodes will be found in incremental numbers
challenging the pulmonologist to make decisions about fur-
ther diagnostic approach. Incidental findings are defined as
imaging abnormalities not related to the indication for which
the CT is requested.
Prevalences of incidental mediastinal lymphadenopa-
thy are reported between 0.15 and 3%, but a systematic
pathologic analysis of these findings has not been described
so far.1–9 Several studies describe pathologic results of me-
diastinal masses in patients of unknown cause.10–13 The rates
of malignancy ranged in these studies from 29 to 65% with
entry criteria that varied significantly. A meta-analysis
showed that larger nodes have a higher chance of containing
malignancy.14 The prevalence of malignancy will be lower
when nodes are small as is usually the case when detected by
incidence on CT. This prospective study with patients re-
ferred from eight different hospitals describes the extend,
size, metabolic activity, and pathologic findings of inciden-
tally detected mediastinal lymph nodes.
PATIENTS AND METHODS
Study Entry Criterium
Patients with at least one enlarged mediastinal lymph node
(shortest diameter of10 mm) were selected for the study when
this incidental finding was detected on CT of the thorax made
for a wide range of indications other than the analysis or
staging of any neoplasm. One patient was analyzed although
the shortest diameter of nodes did not reach 10 mm. Patients
with a poor performance score precluding the consequences
of further diagnostic analysis were excluded.
Imaging and Evaluation of Nodal Disease
Patients were referred from eight different hospitals.
CT scan of the thorax was performed according to local
protocols. One of the authors (J.S.) reviewed all CT scans; all
visible mediastinal nodes were measured along the shortest
axis; and the mediastinal position was classified according to
the International Association for the Study of Lung Cancer.15
In only a limited number of patients, a positron emission tomog-
raphy (PET) was performed, with fluoro-2-deoxyglucose (FDG)
in the mediastinal nodes determined (GE Discovery ST PET-CT
scanner; General Electric, Milwaukee, WI).
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Ultrasound-Guided Biopsies and Pathologic
Analysis
Mediastinal lymph nodes were approached with endo-
scopic ultrasound (EUS) or endobronchial ultrasound
(EBUS) for a diagnostic aspiration or biopsy. EUS and EBUS
were performed with Pentax ultrasound endoscopes (FG-36
UX, FG-34 UX, and EB-1970 UK; Pentax, Tokyo, Japan)
with a Hitachi EUB-5500 processor (Hitachi, Tokyo, Japan).
The fine needle aspiration (FNA) biopsies were performed
under conscious sedation with midazolam and with local
anesthesia that was sprayed in the oropharynx (lidocain 1%)
and lidocain gel 20 mg/ml. Per nodal site, three to four needle
passes were performed, and at least two aspirates were
smeared on slides. Remaining aspirate was deposited in a
fixative medium (carbowax 2% [polyethyleenglycol 20 g in
ethanol 96% methylated and filled up to 1000 ml with water])
for immunohistochemical staining.
RESULTS
Patient Selection
From August 2005 until December 2010, 83 of 1530
patients met the inclusion criteria of our study. They under-
went EUS or EBUS for analysis of incidentally detected
mediastinal lymphadenopathy and if possible FDG-PET. CT
was always available.
Patient Characteristics
Table 1 shows the characteristics of 83 patients (61 men
and 22 women) with a median age of 59 years (range 27–87
years). All patients were referred for EUS-FNA (81) or
EBUS-transbronchial needle aspiration (2) of incidentally
detected lymph nodes on CT scans for a variety of indications
(Table 1). Most CT scans were angio-CT scans made in the
workup of pulmonary embolism (43 patients). Other indica-
tions were pulmonary infiltrative disease (5 patients), pleural
disease (8 patients), parenchymatous disease (3 patients),
health screening scans (2 patients), coronary angiography (2
patients), and a remaining group with other indications (20
patients).
Numbers and Sizes of Mediastinal Nodes
In our patients, nodes of all sizes were visible on CT
scans in at least three levels (according to the Naruke clas-
sification), and in some patients, lymph nodes were visible on
CT at all sites. The median number of sites with visible nodes
was 7 (range 3–9). The median number of lymph nodes of at
least 10 mm was 3 (range 0–8).
Table 1 shows the numbers of patients with different
lymph node sizes at any mediastinal site. The median number
of involved mediastinal sites is also described in Table 1. In
64 patients, hilar lymphadenopathy was also evident. In 19
patients, hilar node enlargement was absent. Table 2 demon-
strates the nodal size, subdivided into several size categories,
for specified mediastinal sites.
FDG Uptake in Mediastinal Nodes
PET scans had been performed in 29 patients. Increased
FDG uptake in mediastinal nodes was demonstrated in 25
patients (inadequate aspirates, 3; reactive lymphoid change,
16; granulomatous inflammation compatible with sarcoidosis,
5; and granulomatous inflammation staining positive for my-
cobacteria, 1). In four patients, there was no increased FDG
uptake observed (all reactive lymphoid change).
Pathologic Analysis
Table 2 describes the results of pathologic analysis.
Cytologic aspirates were derived from 80 patients. In
two patients, introduction of the endoscope failed, and
in one patient, nodes were not detected with ultrasound. In
four patients, the aspirates were considered inadequate for
pathologic analysis.
Guided by ultrasound, subcarinal nodes were biopsied
in 67 patients, the aortic window (locations 4L and 5) in 34
patients, location 8 in 2 patients, and both locations 2L and
4R in 1 patient. In 76 of 80 patients, the quality of aspirated
material allowed an adequate pathologic analysis.
In 55 patients, the aspirates showed many lymphocytes
and were considered reactive without a classifying diagnosis.
Eighteen patients had a granulomatous inflammatory reaction
compatible with sarcoidosis. One patient also had a granulo-
matous disorder and acid-fast mycobacteria with Ziehl-Neel-
TABLE 1. Patient Characteristics of 83 Incidentally
Encountered Mediastinal Lymphadenopathy
N Median (Range)
Patients 83
Age (yr) 59 (27–87)
Gender
Male 61
Female 22
Indications for CT scan
Suspected pulmonary embolism 43
Pleural disease on chest x-ray 8
Suspected interstitial pulmonary disease 8
Persistent pulmonary infiltrate on chest x-ray 5
General internal analysis 5
General pulmonologic analysis 3
Imaging of benign pulmonary abnormalities 3
Commercial screening 2
Coronary angiography 2
Analysis ascending aorta 2
Othera 2
Mediastinal locations
All measurable nodes 83 7 (3–9)
Nodes of at least 10 mm 82 3 (0–8)
10–15 mm 79 3 (1–6)
16–20 mm 38 1 (1–4)
21–30 mm 21 1 (1–3)
30 mm 2 1
Hilar nodal enlargement
Yes 64
No 19
a Mediastinal lymphadenopathy as incidental finding on MRI for cervical radicular
syndrome and exclusion of a primary malignancy in the workup of an abnormal cerebral
MRI.
MRI, magnetic resonance imaging; CT, computed tomography.
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son stain. Conventional culture and a polymerase chain reac-
tion for mycobacteria were negative. One patient had a
bronchogenic cyst.
In a patient with a history of breast cancer, a CT scan
was performed to analyze loculated pleural fluid without
pathologic evidence of a malignancy. The enlarged medias-
tinal nodes, not visible on normal x-ray, contained metastatic
disease of her breast cancer. In a subset of 21 patients with
conditions frequently associated with mediastinal lymphade-
nopathy (pleural disease, interstitial disease, and infiltrative
disease), lymphocytes were present in 81% and a granuloma-
tous inflammatory pattern in 14% compared with 61 and 24%
for all other patients, respectively.
Follow-Up
A classifying diagnosis was obtained with EUS in 21 of
83 patients. In the 62 patients with no classifying diagnosis,
follow-up data were analyzed. This group consisted of 55
patients with adequate aspirates, 4 patients with inadequate
aspirates, 2 patients in whom introduction of the echoscope
failed, and 1 patient in whom no enlarged lymph nodes were
detected with ultrasound.
Follow-up CT scans were available for 36 of 62 pa-
tients (58%). The scans were made after a median interval of
118 days (range 10–692 days). Decisions for follow-up were
made at the discretion of patients’ own treating physician.
Eleven patients were referred from other hospitals and were
lost to follow-up, and for 16 patients in our own practice, no
follow-up CT scans were requested.
In nine patients, the lymphadenopathy had reduced
spontaneously. In 24 patients, the lymphadenopathy remained
unchanged, and in 2 patients, the lymphadenopathy pro-
gressed both in size and number. In both patients with
progressive lymphadenopathy detected on CT scans after 20
and 23 months of follow-up, the initial EUS-FNA contained
adequate samples without malignant cells. In one patient, a
repeat EUS-FNA after 21 months in subcarinal lymph nodes
showed malignant cells, and this patient was diagnosed with
stage IV non-small cell lung cancer. In the other patient,
metastatic lung cancer was demonstrated by a liver biopsy 22
months after initial EUS-FNA. In this patient with obvious
progression of mediastinal lymphadenopathy, metastatic dis-
ease was not verified as a repeated EUS was not performed.
Revision and comparison of CT scans suggest progression of
already existing lymphadenopathy, but an evident primary
tumor was absent on the initial scans. When the number and
the sizes of enlarged nodes for the patients with malignancy
(developed during follow-up or at initial analysis) are com-
pared with patients without malignancy, there are no differ-
ences.
DISCUSSION
Imaging
In this study, a group of 83 patients referred for sus-
pected pulmonary malignancy were described who had in
common that mediastinal lymphadenopathy was detected
incidentally on CT performed for a variety of indications
other than the analysis of malignancy.
The most characteristic features of these enlarged me-
diastinal lymph nodes is their presence in multiple Naruke
stations, its variable but relatively small size, and the con-
comitant hilar involvement in most patients. There was one
TABLE 2. Nodal Distribution and Pathologic Results of EUS and EBUS
Radiologic Distribution of Mediastinal Nodes
(According to IASLC)
Size of Nodes (mm),
Median (Range)<10 mm 10–15 mm 16–20 mm 21–30 mm >30 mm
2R 41 18 9 1 0 8 (4–26)
4R 26 37 15 4 0 13 (4–27)
2L 39 9 0 0 0 6 (3–15)
4L 35 34 2 0 0 10 (4–16)
5 25 37 8 0 0 11 (5–19)
6 46 18 4 0 0 8 (3–20)
7 8 35 16 18 2 14 (6–35)
8 10 18 6 1 0 11 (4–28)
9 14 7 0 0 0 8 (5–15)
Pathologic results
Lymphocytes 55
Sarcoidosis 18
Metastasis mammacarcinoma 1
Granulomatous inflammation, ZN-positive stains 1
Bronchogenic cyst 1
Inadequate needle aspirate 4
No aspirate acquired 3
EUS, endoscopic ultrasound; EBUS, endobronchial ultrasound; IASLC, International Association for the Study of Lung
Cancer; L, left; R, right; ZN, Ziehl-Neelsen.
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patient in whom the largest nodes measured less than 10 mm.
In 46% (38/83) of patients, the largest measured nodes were
between 10 and 15 mm followed by 26% (22/83) of patients
with maximum nodes of 16 to 20 mm, 24% (20/83) of
patients with largest nodes of 21 to 30 mm, and 2% (2/83)
with nodes measuring more than 30 mm.
The size of mediastinal nodes is predictive for the final
pathologic diagnosis as has been demonstrated in a study
where benign nodes were significantly smaller than malignant
nodes.16 However, the nodes of the patient with breast cancer
metastasis in this study and the two patients who developed
non-small cell lung cancer during follow-up did not differ in
size from other patients.
Incidental mediastinal findings are described in screen-
ing studies for coronary artery disease, but information on
extend and size of these findings is scarce.1,2,4–7 Lung cancer
screening studies also report prevalences of nonpulmonary
incidental findings, but details of mediastinal incidental find-
ings are limited or absent.3,8,9
If imaging was expanded with FDG-PET, the majority
of patients demonstrated increased FDG uptake in their
nodes. It is debatable whether PET is indicated in patients
without radiologic evidence of primary lung tumors. All but
1 of 29 patients in whom PET was performed had at least 1
lymph node measuring 10 mm or more in short-axis diameter.
Remarkably, the only patient with nodes smaller than 10 mm
developed lung cancer with confirmed subcarinal metastatic
disease. PET offered in our study added no value to CT in
incidentally detected mediastinal nodes because reactive in-
flammatory diseases also showed metabolic activity and
hence did not discriminate from malignant disease.
Pathology
In our study, the majority of incidental mediastinal
findings showed a reactive inflammatory pattern on patho-
logic analysis, sometimes compatible with sarcoidosis as
might be expected from imaging results. Granulomatous
inflammatory reactions could be expected relatively more
often in patients with conditions with pleural, interstitial,
or infiltrative disease. In a screening study in asbestos
workers (1% of patients), mediastinal lymphadenopathy
was reported, and all lesions were proved to be benign.9
The size of the detected mediastinal nodes was not pro-
vided, but because this was a screening study, the lesions
were presumably small in size.
In a study of 1520 lung cancer screening participants,
incidental mediastinal findings (2 lymphomas) were reported,
but the prevalence of incidentally detected mediastinal
lymphadenopathy was not described.8
Malignancy was found in only one patient in our study.
This patient had a history of breast cancer, and so, this finding
was not unexpected. In all other patients, malignancy was not
observed. These findings conflict with the high pretest prob-
ability of malignancy in patients with mediastinal lymphade-
nopathy of unknown cause in former series.10–13 Critical is
how patients are selected. In a study of isolated mediastinal
lymphadenopathy, EBUS-transbronchial needle aspiration re-
sulted in a diagnosis of malignancy in 60% (33/55) of
patients.12 All patients in this study had suspected lymphoma,
29% (16/55) patients had a history of malignancy, and ex-
cluded were patients with typical clinicoradiologic features of
sarcoidosis. This study did not specify the size and number of
mediastinal nodes. Neither were these features described in
two studies reporting malignancy in 29% (40/140) and 65%
(22/34) of patients.10,13 Finally, in 61% (46/75) of patients,
malignancy was observed in subcarinal nodes but these were
at least 25 mm.11 In a subgroup of patients analyzed for
isolated mediastinal lymph nodes with typical clinicoradio-
logic features suggestive for sarcoidosis, this diagnosis was
confirmed in 93% (26/28) of patients but 1 of 28 had malig-
nancy.17
Our study population cannot be compared with the
patients in these studies because of different entry criteria and
lacking information on number and size of mediastinal nodes.
Regarding our own results in patients with high rates of hilar
lymphadenopathy and multiple mediastinal nodes, the num-
ber of patients with a granulomatous inflammatory reaction
seems small. The difference of these results with our findings
can be explained by the fact that the incidental nodes in our
study were relatively small in size and mostly could not be
detected with normal chest radiographs.
Follow-Up
In the literature, there are no follow-up data of inciden-
tal mediastinal findings. In our study with a deliberate follow-
up, determined by the treating physicians, follow-up CT scan
was available in more than half of the patients without a
classifying diagnosis of incidental mediastinal findings. Two
of 62 patients (3%) developed lung cancer in nodes that had
been evaluated initially with EUS-FNA. The interval of
detection of lung cancer was almost 2 years in both patients.
Based on the follow-up findings in this study, the need for
regular monitoring of incidentally detected lymphadenopathy
with CT scans is debatable.
Regarding the pathologic diagnoses in this study, the
probability to detect a disease that needs treatment is very
low (although an exception could be made for patients with
a history of malignancy). This counterweights the low
threshold to apply modern endosonographic techniques
because of their favorable safety profile and high diagnos-
tic accuracy.18,19
CONCLUSION
Incidentally detected lymphadenopathy often worries
pulmonologists leading to further diagnostic procedures. This
explorative study demonstrates that incidentally detected me-
diastinal findings are mainly a manifestation of reactive
inflammatory origin in mainly multiple, slightly enlarged
mediastinal lymph nodes. Our study does not support a very
aggressive diagnostic approach of these nodes except for
patients with known malignancy or a history of malignancy.
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